The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis.

Bonnie I Glanz Jonathan ZurawskiEmily C CasadyRebecca ShamahMira WeinerTanuja ChitinisHoward L WeinerBrian C Healy

Published in: Multiple sclerosis journal - experimental, translational and clinical (2021)

We observed significant improvements across multiple mental HRQOL domains at 12 months in individuals treated with ocrelizumab. These findings support the use of HRQOL measures to provide a subjective measure of treatment impact that complements traditional outcomes.

Keyphrases

multiple sclerosis
mental health
type diabetes
metabolic syndrome
sleep quality
combination therapy
glycemic control